Cyclic ADP ribose is a novel regulator of intracellular Ca2+ oscillations in human bone marrow mesenchymal stem cells.
Bone marrow mesenchymal stem cells (MSCs) are a promising cell source for regenerative medicine. However, the cellular biology of these cells is not fully understood. The present study characterizes the cyclic ADP-ribose (cADPR)-mediated Ca(2+) signals in human MSCs and finds that externally applied cADPR can increase the frequency of spontaneous intracellular Ca(2+) (Ca(2+) (i) ) oscillations. The increase was abrogated by a specific cADPR antagonist or an inositol trisphosphate receptor (IP3R) inhibitor, but not by ryanodine. In addition, the cADPR-induced increase of Ca(2+) (i) oscillation frequency was prevented by inhibitors of nucleoside transporter or by inhibitors of the transient receptor potential cation melastatin-2 (TRPM2) channel. RT-PCR revealed mRNAs for the nucleoside transporters, concentrative nucleoside transporters 1/2 and equilibrative nucleoside transporters 1/3, IP3R1/2/3 and the TRPM2 channel, but not those for ryanodine receptors and CD38 in human MSCs. Knockdown of the TRPM2 channel by specific short interference RNA abolished the effect of cADPR on the Ca(2+) (i) oscillation frequency, and prevented the stimulation of proliferation by cADPR. Moreover, cADPR remarkably increased phosphorylated extracellular-signal-regulated kinases 1/2 (ERK1/2), but not Akt or p38 mitogen-activated protein kinase (MAPK). However, cADPR had no effect on adipogenesis or osteogenesis in human MSCs. Our results indicate that cADPR is a novel regulator of Ca(2+) (i) oscillations in human MSCs. It permeates the cell membrane through the nucleoside transporters and increases Ca(2+) oscillation via activation of the TRPM2 channel, resulting in enhanced phosphorylation of ERK1/2 and, thereby, stimulation of human MSC proliferation. This study delineates an alternate signalling pathway of cADPR that is distinct from its well-established role of serving as a Ca(2+) messenger for mobilizing the internal Ca(2+) stores. Whether cADPR can be used clinically for stimulating marrow function in patients with marrow disorders remains to be further studied.
Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
Rong
R
Tao
Hai-Ying
HY
Sun
Chu-Pak
CP
Lau
Hung-Fat
HF
Tse
Hon-Cheung
HC
Lee
Gui-Rong
GR
Li
D050156:Adipogenesis / Q000187:drug effects; D015153:Blotting, Western; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D036563:Cyclic ADP-Ribose / Q000494:pharmacology*; D006801:Humans; D053496:Inositol 1,4,5-Trisphosphate Receptors / Q000378:metabolism; D059630:Mesenchymal Stem Cells / Q000187:drug effects* / Q000378:metabolism*; D010012:Osteogenesis / Q000187:drug effects; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects; D050053:TRPM Cation Channels / Q000235:genetics / Q000378:metabolism
C506926:ITPR1 protein, human; D053496:Inositol 1,4,5-Trisphosphate Receptors; D012333:RNA, Messenger; D050053:TRPM Cation Channels; C121934:TRPM2 protein, human; D036563:Cyclic ADP-Ribose; D002118:Calcium
Stem Cells. 2008 Nov;26(11):2855-64
18687991
Am J Physiol Cell Physiol. 2007 Nov;293(5):C1561-7
17699636
Haematologica. 2009 Feb;94(2):173-84
19066333
Mol Cell. 2005 Apr 1;18(1):61-9
15808509
Science. 1999 Apr 2;284(5411):143-7
10102814
Blood. 2005 Feb 15;105(4):1815-22
15494428
Expert Opin Biol Ther. 2010 Jan;10(1):57-71
20078229
J Biol Chem. 2004 May 21;279(21):22066-75
15028729
Arthritis Rheum. 2009 Aug;60(8):2325-32
19644865
Stem Cells Dev. 2010 Mar;19(3):379-94
19032055
Stem Cells. 2009 Oct;27(10):2469-77
19593794
Am J Physiol Cell Physiol. 2006 Mar;290(3):C776-84
16267109
Br J Pharmacol. 2008 Mar;153(6):1324-30
18204483
Nature. 1998 Apr 30;392(6679):933-6
9582075
EMBO J. 2006 May 3;25(9):1804-15
16601673
FASEB J. 2001 Jul;15(9):1610-2
11427502
Curr Mol Med. 2004 May;4(3):239-48
15101682
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7577-82
15890781
Am J Physiol Cell Physiol. 2008 Nov;295(5):C1409-16
18815226
Physiol Rev. 2008 Jul;88(3):841-86
18626062
Ageing Res Rev. 2006 Feb;5(1):91-116
16310414
Biochem Biophys Res Commun. 2006 Sep 15;348(1):301-9
16876113
J Cell Physiol. 2009 Sep;220(3):765-70
19475562
Cell Cycle. 2009 Apr 15;8(8):1168-75
19282669
Nature. 2001 May 31;411(6837):595-9
11385575
Expert Opin Biol Ther. 2010 Feb;10(2):215-30
20088716
FASEB J. 2000 Apr;14(5):680-90
10744625
Mol Cell Biochem. 1999 Mar;193(1-2):115-8
10331647
Annu Rev Pharmacol Toxicol. 2001;41:317-45
11264460
Naunyn Schmiedebergs Arch Pharmacol. 2004 Oct;370(4):227-37
15549272
J Cell Physiol. 2010 Apr;223(1):68-75
20039269
Biochem J. 1999 Feb 1;337 ( Pt 3):491-6
9895292
J Mol Cell Cardiol. 2007 Feb;42(2):295-303
16919679
Cell Calcium. 2002 Oct;32(4):165-74
12379176
Stem Cells. 2004;22(5):675-82
15342932
FASEB J. 2006 Jan;20(1):181-3
16249315
J Cell Mol Med. 2005 Jan-Mar;9(1):25-36
15784162
J Cell Biochem. 2006 Aug 1;98(5):1140-9
16514667
Nat Rev Mol Cell Biol. 2000 Oct;1(1):11-21
11413485
Curr Med Chem. 2004 Apr;11(7):847-55
15078169
FASEB J. 2006 May;20(7):962-4
16585058
Cell Calcium. 2006 Apr;39(4):313-24
16445977
J Biol Chem. 2009 Oct 23;284(43):29335-42
19696022
Curr Mol Med. 2004 May;4(3):227-37
15101681
Cell Cycle. 2007 Dec 1;6(23):2884-9
18000405
Blood. 2005 Jul 1;106(1):59-66
15755902
Int J Radiat Biol. 2010 Mar;86(3):230-7
20201651
Blood Rev. 2006 May;20(3):161-71
16364518
J Cell Physiol. 2005 Nov;205(2):194-201
15880640
Stem Cells. 2005 Mar;23(3):371-82
15749932
Ann N Y Acad Sci. 2004 Dec;1028:176-91
15650244
Biochem Biophys Res Commun. 1996 Nov 21;228(3):838-45
8941363
Cell Calcium. 2003 Aug;34(2):145-56
12810056
Pharmacol Rev. 2004 Dec;56(4):439-513
15602008
Exp Gerontol. 2005 Dec;40(12):926-30
16125890
FASEB J. 2003 Feb;17(2):310-2
12475890
J Biol Chem. 2005 Feb 18;280(7):5343-9
15574424